American Association of Cancer Research (AACR) Annual Meeting 2023: Abstracts to Watch

Looking for detailed coverage of the AACR meeting 2023?

Octavus Consulting got you covered. To gather top notch business intelligence from coverages, conferences, and symposiums, Octavus Consulting work extensively in catering to the needs of the biopharma and life science industries, working on gathering insights on pipeline drugs, breakthrough discoveries, and recent clinical stage developments.?

For Insights report of #AACR 2023 drop a mail on [email protected] with a subject line "AACR 2023"

To continue the series of AACR annual meeting, this year 114th Annual Meeting of the?#AACR 2023?is going to be held on Apr 14-19, 2023 at Orange County Convention Center, Orlando, Florida as well as Virtual. The meeting will be featured in Plenary sessions (5), Clinical trial plenary sessions (4) and mini-symposia (3), major symposia (52), >6,000 poster presentations along with many educational sessions, methods workshops, meet-the-expert sessions, award lectures, and networking opportunities.?

This year, team Octavus gathered few interesting abstracts (full abstract has not revealed yet) to be presented on AACR 2023 and created in a summary reported based on?various targets?that includes:

1. CAR-T Therapies: As it holds great potential to treat disease like cancer, now a days, it’s being assessed for the treatment of various diseases incl. cancers. Advancement in cell therapy is talk of the town and getting support in terms of funding and other facilities from a lot of organizations, Biopharma investor as well as government. This year AACR is going to feature clinical data from Allogene’s ALLO-316, AstraZeneca’s C-CAR031 and AZD0754.?

2. Immunotherapy: Immunotherapy is a broader category in cancer treatment. According to a market analysis, in 2022, the global immunotherapy drug market was estimated at $190.4 B and expected to increase around $351.5 B by 2030.

At AACR, 罗氏公司 , 阿斯利康 , 默克 etc. are going to highlight the full data from Phase 3 study evaluating Tecentriq, Imfinzi, and Keytruda respectively. Anti-PD-L1 Mab, SIRP alpha inhibitor Anti-EGFR x LGR5 bispecific mAb mechanism-based molecule like Merus’s Petosemtamab, Boehringer Ingelheim’s BI765063 etc. will be highlighted

3. Antibody Drug Conjugate (ADC): ADCs has always been the focal point. No. of ADCs molecules are anticipated to present at AACR 2023 that could be of interest for biopharma investors, researchers as well as competitors. ?AZD5363, ABBV-319, TAK-500 are some of them.

4. KRAS/RAF Mutation: AACR will cover clinical data of Kras/Raf signalling molecules being developed by the players like. Novartis, Amgen, Lilly, Roche and others. Frontier Medicines and Revolution Medicines are also on the way to challenge Amgen, Novartis and others whereas, Kinnate will highlight the P-I clinical data for exarafenib.

A mini-symposium has been scheduled on 17th April entitled “Targeting the Kras pathway in the clinic” will cover Kras G12C-targeting small molecules. Additional molecules being developed by the players like. Amgen and Mirati, Lilly, Roche and Innovent will also be highlighted.

5. EGFR/FGFR Mutation: The Phase III data of ARV-471 being evaluated in collaboration with Pfizer will be the most awaited data additionally, BAY 2927088, LOXO-435 etc. is planned to flaunt in the conference

For Insights report of #AACR 2023 drop a mail on [email protected] with a subject line "AACR 2023"